Skip to main content
Clinical Trials/ACTRN12607000512426
ACTRN12607000512426
Completed
Phase 3

Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised phase III trial

Melanoma and Skin Cancer (MASC) Trials0 sites215 target enrollmentOctober 9, 2007

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Melanoma brain metastases
Sponsor
Melanoma and Skin Cancer (MASC) Trials
Enrollment
215
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 9, 2007
End Date
September 23, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Melanoma and Skin Cancer (MASC) Trials

Eligibility Criteria

Inclusion Criteria

  • 1\. 1\-3 intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or stereotactic irradiation. 2\. Life expectancy of at least 6 months 3\. Aged 18 years or older 4\. WBRT must be within 8 weeks of completion of localised treatment and within 4 weeks of randomisation 5\. Able to have an MRI brain scan with contrast. ‘estimated Glomerular Filtrate Rate’ (eGFR) is adequate at the discretion of the radiologist and capable of having gadolinium\-containing contrast medium for MRI as per practice guidelines 6\. Complete localised treatment of all these metastases no more than 6 weeks prior to randomisation 7\. An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at randomisation 8\. CT scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must be within 12 weeks of randomisation 9\. Serum Lactate Dehydrogenase (LDH) must be \= or \< 2 x upper limit of normal 10\. Able to provide written informed consent

Exclusion Criteria

  • 1\.Any untreated intracranial disease
  • 2\.Any previous intracranial treatment (surgical excision and/or stereotactic irradiation treatment and/or WBRT) prior to this diagnosis of intracranial melanoma
  • 3\.Evidence of leptomeningeal disease on pre\-local treatment MRI scan
  • 4\.Patients with prior cancers, except:
  • oThose diagnosed more than five years ago with no evidence of disease recurrence within this time;
  • oSuccessfully treated basal cell and squamous cell skin carcinoma;
  • oCarcinoma in\-situ of the cervix
  • 5\.A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol
  • 6\.Positive urine pregnancy test for women of childbearing potential within a week of registration onto the trial

Outcomes

Primary Outcomes

Not specified

Similar Trials